Charting the course of medical laboratories in a changing environment

Clinica Chimica Acta

Volumn 319, Issue 2, 2002, Pages 87-100

  Plebani, Mario ^a,b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Centre of Biomedical Research of Castelfranco Veneto   (Italy)

Author keywords

Change; Clinical outcomes; Clinical role; Evidence based laboratory medicine; Quality of services

Indexed keywords

ARTICLE; CLINICAL LABORATORY; COMPETENCE; CONSULTATION; DIAGNOSTIC ACCURACY; EVIDENCE BASED MEDICINE; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH SERVICE; LABORATORY PERSONNEL; LABORATORY TEST; MEDICAL DECISION MAKING; MEDICAL RESEARCH; PATIENT CARE; PRIORITY JOURNAL; SKILL;

CLINICAL LABORATORY TECHNIQUES; DECISION MAKING; DELIVERY OF HEALTH CARE; EDUCATION, CONTINUING; EVIDENCE-BASED MEDICINE; HUMANS; LABORATORIES, HOSPITAL; LABORATORY TECHNIQUES AND PROCEDURES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY CONTROL; TECHNOLOGY, MEDICAL; TIME FACTORS; TOTAL QUALITY MANAGEMENT;

EID: 0037150245     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00028-1     Document Type: Article

References (69)

1. The changing face of clinical laboratories
2. The clinical importance of laboratory reasoning
3. Mistakes in a stat laboratory: Types and frequency
4. Laboratory adaptations - Changing expectations
5. Laboratory costs in the context of disease
6. Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits
7. Large differences in laboratory utilization between hospitals in Sweden
8. Evidence-based medicine: Its application to laboratory medicine
9. Use of computer terminals on wards to access emergency test results: A retrospective study
10. Techniques to improve physicians' use of diagnostic tests
11. Continuous improvement, quality control, and cost containment in clinical laboratory testing
12. The emergency department
13. Point-of-care testing: The hybrid laboratory and knowledge optimization
14. Evaluating stat testing options in an academic health center: Therapeutic turnaround time and staff satisfaction
15. Optimal analytical performance for POCT
16. Molecular detection of Mycobacterium tuberculosis: Impact on patient care
17. It's time for a change to a troponin standard
18. Myocardial infarction redefined - A consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for a redefinition of Myocardial infarction
19. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
20. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
21. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
22. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
23. Effect of statin therapy on C-reactive protein levels
24. Identification of tissue transglutaminase as the autoantigen of celiac disease
25. Diagnosis of celiac sprue
26. Human recombinant tissue transglutaminase ELISA: An innovative diagnostic assay for celiac disease
27. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine
28. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology
29. Managing testicular cancer
30. Incidence of aberrant phenotypes in a large series of B-cell chronic lymphoproliferative disorders. Implications for minimal residual disease
31. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease
32. The immunologic detection of minimal residual disease in acute leukemia
33. Minimal residual disease in acute myeloid malignancies
34. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: Current status and future directions
35. Automated assay for HER-2/neu in serum
36. Quantification of HER-2/neu gene amplification by competitive PCR using fluorescent melting curve analysis
37. Detection and clinical importance of micrometastatic disease
38. CEA mRNA identification in peripheral blood is feasible for colorectal, but not for gastric on pancreatic cancer staging
39. Free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: Which is clinically effective and when?
40. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes
41. For the International Federation of Clinical Chemistry Scientific Division Committee on Molecular Biology Techniques
42. The clinical role of clinical biochemistry
43. Narrative interpretations for clinical laboratory evaluation
44. Experience with assessing the quality of comments on clinical biochemistry reports
45. Changing face of medical curricula
46. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
47. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and nutrition (EPIC-Norfolk)
48. Molecular medicine and hemochromatosis: At the crossroads
49. Screening for mutations and polymorphisms in the genes HCNH2 and KCNE2 encoding the cardiac HERG/MiRPI ion channel: Implication for acquired and congenital long Q-T syndrome
50. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2)
51. Common hereditary cancers and implications for primary care
52. Evidence-based medicine: A new approach to teaching the practice of medicine
53. Evidence-based medicine: Past, present and future
54. Evidence-based medicine: What it is and what it isn't
55. Evidence-based laboratory medicine: Supporting decision-making
56. Strategies to set global analytical quality specifications in laboratory medicine
57. Analytical performance characteristics should be judged against objective quality specifications
58. Clinical audit and the contribution of the laboratory to clinical outcome
59. The need for an outcomes research agenda for clinical laboratory testing
60. Laboratory-related outcomes in healthcare
61. Which surrogate marker can be used to assess the effectiveness of the laboratory and its contribution to clinical outcome?
62. Analytical bias specifications based on the analysis of effects on performance of medical guidelines
63. Educational programs in US Medical Schools, 1998-1999
64. Impact of formal continuing medical education: Do conferences, workshop, rounds, and other traditional continuing education activities change physician behaviour or health care outcomes?